Rigosertib (ON-01910)

Catalog No.S1362

For research use only.

Rigosertib (ON-01910) is a non-ATP-competitive inhibitor of PLK1 with IC50 of 9 nM in a cell-free assay. It shows 30-fold greater selectivity against Plk2 and no activity to Plk3. Rigosertib inhibits PI3K/Akt pathway and activates oxidative stress signals. Rigosertib induces apoptosis in various cancer cells. Phase 3.

Rigosertib (ON-01910) Chemical Structure

CAS No. 1225497-78-8

Selleck's Rigosertib (ON-01910) has been cited by 29 publications

Purity & Quality Control

Choose Selective PLK Inhibitors

Other PLK Products

Biological Activity

Description Rigosertib (ON-01910) is a non-ATP-competitive inhibitor of PLK1 with IC50 of 9 nM in a cell-free assay. It shows 30-fold greater selectivity against Plk2 and no activity to Plk3. Rigosertib inhibits PI3K/Akt pathway and activates oxidative stress signals. Rigosertib induces apoptosis in various cancer cells. Phase 3.
Targets
PLK1 [1]
(Cell-free assay)
PDGFR [1]
(Cell-free assay)
Bcr-Abl [1]
(Cell-free assay)
Flt1 [1]
(Cell-free assay)
Src [1]
(Cell-free assay)
Click to View More Targets
9 nM 18 nM 32 nM 42 nM 155 nM
In vitro

Rigosertib is non-ATP-competitive inhibitor to PLK1 with IC50 of 9 nM. Rigosertib also exhibits inhibition against PLK2, PDGFR, Flt1, BCR-ABL, Fyn, Src, and CDK1, with IC50 of 18-260 nM. Rigosertib shows cell killing activity against 94 different tumor cell lines with IC50 of 50-250 nM, including BT27, MCF-7, DU145, PC3, U87, A549, H187, RF1, HCT15, SW480, and KB cells. While in normal cells, such as HFL, PrEC, HMEC, and HUVEC, Rigosertib has little or no effect unless its concentration is greater than 5-10 μM. In HeLa cells, Rigosertib (100-250 nM) induces spindle abnormalities and apoptosis. [1] Rigosertib also inhibits several multidrug resistant tumor cell lines, including MES-SA, MES-SA/DX5a, CEM, and CEM/C2a, with IC50 of 50-100 nM. In DU145 cells, Rigosertib (0.25-5 μM) blocks cell cycle progression in G2/M phase, results in an accumulation of cells containing subG1 content of DNA, and activates apoptotic pathways. In A549 cells, Rigosertib (50 nM-0.5 μM) induces loss of viability and caspase 3/7 activation. [2] In a recent study, Rigosertib induces apoptosis in chronic lymphocytic leukemia (CLL) cells without toxicity against T-cells or normal B-cells. Rigosertib also abrogates the pro-survival effect of follicular dendritic cells on CLL cells and reduces SDF-1-induced migration of leukemic cells. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
T47D NYW4T2tmS3m2b4TvfIlkcXS7IHHzd4F6 NXG0cZRYPzJiaILz MVnDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDUOFdFKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGdKPTBiPTCwMlAyKM7:TT6= NYLETGlYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0OlM6PDRpPkKxOFY{QTR2PD;hQi=>
MDA468 NVLScFZoS3m2b4TvfIlkcXS7IHHzd4F6 NF7xeIs4OiCqcoO= NX7ZW|huS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUSDNE[4JINmdGy|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFfJOVAhRSByLkCyJO69VS5? M3PQOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNE[zPVQ1Lz5{MUS2N|k1PDxxYU6=
MCF7 MVTDfZRwfG:6aXPpeJkh[XO|YYm= NWfTc|NUPzJiaILz MYDDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGdKPTBiPTCwMlA2KM7:TT6= NUDBRmZsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0OlM6PDRpPkKxOFY{QTR2PD;hQi=>
HCT116 NFTibpREgXSxdH;4bYNqfHliYYPzZZk> MoHNO|IhcHK| NF;0dplEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJS1RzMU[gZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiR1m1NEA:KDBwMEWg{txONg>? MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTR4M{m0OEc,OjF2NkO5OFQ9N2F-
MDA468 MlSwR5l1d3SxeHnjbZR6KGG|c3H5 M4PiOlQ5KGi{cx?= M3yxUGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1FSTR4ODDj[YxteyCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCJSUWwJF0hOC5|MEKg{txONg>? NFH1NFM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUS2N|k1PCd-MkG0OlM6PDR:L3G+
MDA468 MYTDfZRwfG:6aXPpeJkh[XO|YYm= M3;VNVI1KGi{cx?= M{XybmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1FSTR4ODDj[YxteyCjZoTldkAzPCCqcoOgZpkhVVSWIHHzd4F6NCCJSUWwJF0hOC54MEGg{txONg>? MnTrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF2NkO5OFQoRjJzNE[zPVQ1RC:jPh?=
MRC5 MorPR5l1d3SxeHnjbZR6KGG|c3H5 NVO1WGs3PzJiaILz M{K3O2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1TSzViY3XscJMh[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhT0l3MDC9JFAvPzFizszNMi=> M1HkV|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNE[zPVQ1Lz5{MUS2N|k1PDxxYU6=
MCF7 NFjZVVZHfW6ldHnvckBie3OjeR?= NEHWRYgyKHWP M4DtR21mfGGkb3zpZ{B{fGGkaXzpeJkhd2ZidHjlJINwdXCxdX7kJIlvKGi3bXHuJG1ETjdiY3XscJMh[XRiMTD1US=> NYrDbG8{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0OlM6PDRpPkKxOFY{QTR2PD;hQi=>
MRC5 NYficINmTnWwY4Tpc44h[XO|YYm= M1O0WVEhfU1? Mm\QUYV1[WKxbHnjJJN1[WKrbHn0fUBw\iC2aHWgZ49ueG:3bnSgbY4hcHWvYX6gUXJEPSClZXzsd{BifCBzIIXN NEnkdFE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUS2N|k1PCd-MkG0OlM6PDR:L3G+
K562 M1PEUmN6fG:2b4jpZ4l1gSCjc4PhfS=> MmfRPVYhcHK| NGLzUWNEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBMPTZ{IHPlcIx{KGGodHXyJFk3KGi{czDifUB1enmyYX6gZox2\SCneHPseZNqd25iYYPzZZktKEmFNUCgQUAxNjByN{Wg{txONg>? NXW2So5HRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG4NVI1OjFpPkKxPFEzPDJzPD;hQi=>
DU145 M3rOVWN6fG:2b4jpZ4l1gSCjc4PhfS=> M2XEcVk3KGi{cx?= MYDDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDEWVE1PSClZXzsd{Bi\nSncjC5OkBpenNiYomgeJJ6eGGwIHLseYUh\XilbIXzbY9vKGG|c3H5MEBKSzVyIE2gNE4xPzVizszNMi=> M{\OWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOEGyOFIyLz5{MUixNlQzOTxxYU6=
HeLa NGLZ[GpCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= NF3rcpc4OiCqcoO= NVm0cZVTSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDI[WxiKGOnbHzzJIF{e2W|c3XkJIF{KGOnbHyg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygS2k2OCB;IECuNFEzKM7:TT6= NULpT4FwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0O|E5PzNpPkK0OFcyQDd|PD;hQi=>
LNCAP M4S2WWFvfGmycn;sbYZmemG2aY\lJIF{e2G7 Ml:3O|IhcHK| MmHhRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDBVkBxd3OrdHn2[UBpfW2jbjDMUmNCWCClZXzsd{Bie3Onc4Pl[EBieyClZXzsJIdzd3e2aDDpcohq[mm2aX;uJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGdKPTBiPTCwMlAzPSEQvF2u NGDNR5o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NES3NVg4Oyd-MkS0O|E5PzN:L3G+
PANC1 MoDQRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? Mnu4O|IhcHK| MV3BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFCDTlOxJINmdGy|IHHzd4V{e2WmIHHzJINmdGxiZ4Lve5RpKGmwaHnibZRqd25iYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiR1m1NEA:KDBwMEO5JO69VS5? NGLhcnU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NES3NVg4Oyd-MkS0O|E5PzN:L3G+
MCF7 NWKwRYNmSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= MWO3NkBpenN? NVrzSJd[SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBGWiCyb4PpeIl3\SCqdX3hckBOS0Z5IHPlcIx{KGG|c3Xzd4VlKGG|IHPlcIwh\3Kxd4ToJIlvcGmkaYTpc44h[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhT0l3MDC9JFAvODVizszNMi=> MlTwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2N{G4O|MoRjJ2NEexPFc{RC:jPh?=
MCF7 NWfMeYx6SW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= NHvCS3k4OiCqcoO= NULRbngxSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIF{e2W|c3XkJIF{KGOnbHyg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygS2k2OCB;IECuNFUh|ryPLh?= MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR5MUi3N{c,OjR2N{G4O|M9N2F-
MDA-MB-231 NUPJTYM{SW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= NUWwSoNSPzJiaILz M3\YfmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgSXIhdmWpYYTpeoUhcHWvYX6gUWRCNU2ELUKzNUBk\WyuczDhd5Nme3OnZDDhd{Bk\WyuIHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFfJOVAhRSByLkC1O{DPxE1w MoW2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2N{G4O|MoRjJ2NEexPFc{RC:jPh?=
A2780 M3;T[WFvfGmycn;sbYZmemG2aY\lJIF{e2G7 NH3pO|E4OiCqcoO= MkiwRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCDMke4NEBk\WyuczDhd5Nme3OnZDDhd{Bk\WyuIHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFfJOVAhRSByLkC2NkDPxE1w NIXlUIE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NES3NVg4Oyd-MkS0O|E5PzN:L3G+
HCT116 MWjBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? Mon4O|IhcHK| NYfVeVhQSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[XO|ZYPz[YQh[XNiY3XscEBoem:5dHigbY5pcWKrdHnvckBi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBIUTVyIE2gNE4xPyEQvF2u M2fRTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEexPFc{Lz5{NES3NVg4OzxxYU6=
DU145 NXHMWWtGSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= M1H0cVczKGi{cx?= M3LoXWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgRXIhdmWpYYTpeoUhcHWvYX6gSHUyPDViY3XscJMh[XO|ZYPz[YQh[XNiY3XscEBoem:5dHigbY5pcWKrdHnvckBi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBIUTVyIE2gNE4xPzVizszNMi=> M{DC[|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEexPFc{Lz5{NES3NVg4OzxxYU6=
A2780 NGXURlZHfW6ldHnvckBie3OjeR?= MmrRNE4zPSC3TR?= NF:1Z5AzPCCqcoO= M1rJNXJm\HWldHnvckBqdiCFRFOyOWMhdGW4ZXygbY4hcHWvYX6gRVI4QDBiY3XscJMh[XRiMD6yOUB2VSCjZoTldkAzPCCqcoOgZpkhX2W|dHXyckBjdG:2IHHuZYx6e2m| M3n1W|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEexPFc{Lz5{NES3NVg4OzxxYU6=
A2780 MV\BdI9xfG:|aYOgZZN{[Xl? NGPLW5gxNjJ3IIXN MmXBNlQhcHK| NHy0fGdKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m|IHnuJIh2dWGwIFGyO|gxKGOnbHzzJIF{e2W|c3XkJIF{KGOjc4Dhd4UuOy95IHHjeIl3[XSrb36gZZQhOC5{NTD1UUBi\nSncjCyOEBpenNiYomgeZNqdmdiQYDvMW9PTSCqb33v[4Vv\W:3czDjZZNx[XOnLUOvO{BscXR? MoDrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2N{G4O|MoRjJ2NEexPFc{RC:jPh?=
A2780 NEHGd3NHfW6ldHnvckBie3OjeR?= NGW5fGgxNjJ3IIXN NFnXNnYzPCCqcoO= Mlm1VoVlfWO2aX;uJIlvKE2lbEGgcIV3\WxiaX6gbJVu[W5iQUK3PFAh[2WubIOgZZQhOC5{NTD1UUBi\nSncjCyOEBpenNiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{ MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR5MUi3N{c,OjR2N{G4O|M9N2F-
Assay
Methods Test Index PMID
Western blot pAbl / Abl / PCrk-L / Crk-L / Cleaved caspase3 / Cleaved PARP / pHistone H2A.X 26008977
Immunofluorescence p-ATF / COX IV 27764820
Growth inhibition assay GI50 ; Cell viability 29108241 27764820
In vivo In mouse xenograft models of Bel-7402, MCF-7, and MIA-PaCa cells, Rigosertib (250 mg/kg) markedly inhibits tumor growth. [1] Rigosertib (200 mg/kg) shows inhibition on tumor growth in a mouse xengraft model of BT20 cells. [2]

Protocol (from reference)

Kinase Assay:[1]
  • In vitro enzyme assays for PLK1:

    Recombinant PLK1 (10 ng) is incubated with different concentrations of Rigosertib in a 15 µL reaction mixture (50 mM HEPES, 10 mM MgCl2, 1 mM EDTA, 2 mM Dithiothreitol, 0.01% NP-40 [pH 7.5]) for 30 min at room temperature. Kinase reactions are performed for 20 min at 30 °C in a volume of 20 µL (15 µL enzyme + inhibitor, 2 µL 1 mM ATP), 2 µL of γ32P-ATP (40 μCi), and 1 µL of recombinant Cdc25C (100 ng) or casein (1 μg) substrates. Reactions are terminated by boiling for 2 min in 20 µL of 2× Laemmli buffer. Phosphorylated substrates are separated by 18% SDS-PAGE. The gels are dried and exposed to X-ray film for 3-10 min.

Cell Research:[2]
  • Cell lines: A number of tumor cell lines, including BT20, MCF-7, DU145, PC3, U87, A549, H187, RF1, HCT15, HeLa, and Raji cells
  • Concentrations: 1 nM - 10 μM, dissolved in DMSO as stock solution.
  • Incubation Time: 96 hours
  • Method: Cells are grown in either DMEM or RPMI supplemented with 10% fetal bovine serum and 1 unit/mL penicillin-streptomycin solution. Tumor cells are plated into six-well dishes at a density of 1 × 105cells/mL/well, and Rigosertib is added 24 hours later at various concentrations. Cell counts are determined from duplicate wells after 96-hour of treatment. The total number of viable cells is determined by trypan blue exclusio
Animal Research:[1]
  • Animal Models: Mouse (female athymic, NCR-nu/nu) xenograft models of Bel-7402, MCF-7, and MIA-PaCa cells
  • Dosages: 250 mg/kg
  • Administration: Intraperitonially

Solubility (25°C)

In vitro

DMSO 95 mg/mL
(200.64 mM)
Water 95 mg/mL
(200.64 mM)
Ethanol Insoluble

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
water
For best results, use promptly after mixing.

95mg/mL

Chemical Information

Molecular Weight 473.47
Formula

C21H24NNaO8S

CAS No. 1225497-78-8
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles COC1=C(C=C(C=C1)CS(=O)(=O)C=CC2=C(C=C(C=C2OC)OC)OC)NCC(=O)[O-].[Na+]

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04177498 Recruiting Drug: Rigosertib Sodium|Other: Quality-of-Life Assessment Recessive Dystrophic Epidermolysis Bullosa Thomas Jefferson University|Onconova Therapeutics Inc. August 24 2021 Early Phase 1
NCT02075034 Withdrawn Drug: rigosertib Myelodysplastic Syndrome Onconova Therapeutics Inc. May 2014 Phase 1
NCT02030639 Completed Drug: rigosertib Healthy Onconova Therapeutics Inc. January 2014 Phase 1
NCT01928537 Completed Drug: rigosertib sodium Myelodysplastic Syndromes|Refractory Anemia With Excess Blasts|Chronic Myelomonocytic Leukemia|Cytopenia Onconova Therapeutics Inc. August 2013 Phase 3
NCT01807546 Completed Drug: rigosertib Head and Neck Squamous Cell Carcinoma|Anal Squamous Cell Carcinoma|Lung Squamous Cell Carcinoma|Cervical Squamous Cell Carcinoma|Esophageal Squamous Cell Carcinoma|Skin Squamous Cell Carcinoma|Penile Squamous Cell Carcinoma Onconova Therapeutics Inc. March 2013 Phase 2
NCT01168011 Completed Drug: rigosertib Solid Tumor Onconova Therapeutics Inc. July 2010 Phase 1

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Rigosertib (ON-01910) | Rigosertib (ON-01910) supplier | purchase Rigosertib (ON-01910) | Rigosertib (ON-01910) cost | Rigosertib (ON-01910) manufacturer | order Rigosertib (ON-01910) | Rigosertib (ON-01910) distributor